Keisuke Suzuki1, Tomoyuki Miyamoto2, Masayuki Miyamoto3, Tomoyuki Uchiyama4, Koichi Hirata5. 1. Department of Neurology, Dokkyo Medical University, Tochigi, Japan. Electronic address: keisuke@dokkyomed.ac.jp. 2. Department of Neurology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan. 3. Department of Clinical Medicine for Nursing, Dokkyo Medical University School of Nursing, Tochigi, Japan. 4. Department of Neurology, Dokkyo Medical University, Tochigi, Japan; Neuro-urology and Continence Center, Dokkyo Medical University Hospital, Tochigi, Japan. 5. Department of Neurology, Dokkyo Medical University, Tochigi, Japan.
Abstract
BASEGROUND: Postural abnormalities are refractory complications observed in mid- to late-stage Parkinson's disease (PD). METHODS: We analyzed the effects of istradefylline, a selective adenosine A2A receptor antagonist, on posture in 21 levodopa-treated PD patients from the subanalysis of a three-month open-label study. RESULTS: The subitem score of posture (3.13) on the Movement Disorder Society revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III significantly improved following istradefylline treatment (baseline, 1.3±1.0 points vs 3months, 0.9±0.9 points; p<0.05). Among 18 patients who had postural abnormalities at baseline, defined as 1 point or greater on MDS-UPDRS part III subitem 3.13, posture improved in 9 (50%) and was unchanged in 9 (50%) patients after istradefylline treatment. Improved and unchanged groups did not show differences in baseline characteristics, except for tendency for a higher rate of Hoehn and Yahr stage IV and V (Off state) observed in the improved group. Changes in scores of posture (3.13) did not correlate with those of other MDS-UPDRS part III items, PD Questionnaire-8, PD Sleep Scale-2 and Epworth Sleepiness Scale. CONCLUSION: Based on our preliminary findings, istradefylline could be an effective treatment option for postural abnormalities in mid-stage PD patients.
BASEGROUND: Postural abnormalities are refractory complications observed in mid- to late-stage Parkinson's disease (PD). METHODS: We analyzed the effects of istradefylline, a selective adenosine A2A receptor antagonist, on posture in 21 levodopa-treated PDpatients from the subanalysis of a three-month open-label study. RESULTS: The subitem score of posture (3.13) on the Movement Disorder Society revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III significantly improved following istradefylline treatment (baseline, 1.3±1.0 points vs 3months, 0.9±0.9 points; p<0.05). Among 18 patients who had postural abnormalities at baseline, defined as 1 point or greater on MDS-UPDRS part III subitem 3.13, posture improved in 9 (50%) and was unchanged in 9 (50%) patients after istradefylline treatment. Improved and unchanged groups did not show differences in baseline characteristics, except for tendency for a higher rate of Hoehn and Yahr stage IV and V (Off state) observed in the improved group. Changes in scores of posture (3.13) did not correlate with those of other MDS-UPDRS part III items, PD Questionnaire-8, PD Sleep Scale-2 and Epworth Sleepiness Scale. CONCLUSION: Based on our preliminary findings, istradefylline could be an effective treatment option for postural abnormalities in mid-stage PDpatients.
Authors: C M Massari; L C Constantino; N F Marques; L B Binder; M Valle-León; M López-Cano; V Fernández-Dueñas; F Ciruela; C I Tasca Journal: Purinergic Signal Date: 2020-07-28 Impact factor: 3.765
Authors: Amnon A Berger; Ariel Winnick; Alexandra Welschmeyer; Alicia Kaneb; Kevin Berardino; Elyse M Cornett; Alan D Kaye; Omar Viswanath; Ivan Urits Journal: Neurol Int Date: 2020-12-08